BIA
IOVA icon

Biondo Investment Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Biondo Investment Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-182,555
Closed -$3.04M – 79
2022
Q1 		$3.04M Buy
182,555
+5,092
+3% +$78.7K 0.54% 45
2021
Q4 		$3.39M Buy
177,463
+626
+0.4% +$13.8K 0.56% 44
2021
Q3 		$4.36M Buy
176,837
+3,146
+2% +$74.1K 0.75% 44
2021
Q2 		$4.52M Buy
173,691
+932
+0.5% +$24.2K 0.78% 44
2021
Q1 		$5.47M Sell
172,759
-624
-0.4% -$25.9K 1.09% 39
2020
Q4 		$8.04M Sell
173,383
-8,790
-5% -$349K 1.54% 19
2020
Q3 		$6M Sell
182,173
-315
-0.2% -$9.66K 1.3% 23
2020
Q2 		$5.01M Buy
182,488
+3,089
+2% +$102K 1.26% 29
2020
Q1 		$5.37M Sell
179,399
-4,686
-3% -$124K 1.78% 15
2019
Q4 		$5.09M Sell
184,085
-750
-0.4% -$17.1K 1.18% 30
2019
Q3 		$3.36M Buy
+184,835
New +$4.09M 0.86% 38

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Biondo Investment Advisors's IOVA Position: Q2 2022 in Review

Biondo Investment Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 182,555 shares — an estimated $3.04M sold.

Biondo Investment Advisors first reported a position in IOVA in Q3 2019 and held it in 11 quarters. The position peaked at $8.04M in Q4 2020. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Biondo Investment Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Biondo Investment Advisors sold 182,555 Iovance Biotherapeutics shares in Q2 2022, an estimated $3.04M.
  • Biondo Investment Advisors first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 11 quarters.
  • Biondo Investment Advisors's Iovance Biotherapeutics position peaked at $8.04M in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Biondo Investment Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.